vaccine Archives | Be Korea-savvy
GSK Grants Exclusive Technology License for Clinical-Stage Ebola Vaccines to Sabin Vaccine Institute

GSK Grants Exclusive Technology License for Clinical-Stage Ebola Vaccines to Sabin Vaccine Institute

LONDON and WASHINGTON, Aug. 6 (Korea Bizwire) — GSK and the Sabin Vaccine Institute (Sabin) today announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently [...]

Batavia Biosciences Receives $2.2 Million Follow-up Grant from PATH to Support New Tools for Polio Eradication Era

Batavia Biosciences Receives $2.2 Million Follow-up Grant from PATH to Support New Tools for Polio Eradication Era

Leiden, Jul. 4 (Korea Bizwire) – Today, Batavia Biosciences announces it received a follow-up grant of $2.2 million from PATH – a global organization dedicated to health equity – to develop and manufacture novel oral poliovirus vaccines (nOPV). The project, which is funded by the Bill & Melinda Gates Foundation, aims to protect children worldwide from all [...]

S. Korean Drug Maker Penalized for Cutting Supply of Free Vaccines

S. Korean Drug Maker Penalized for Cutting Supply of Free Vaccines

SEOUL, May 17 (Korea Bizwire) — A supplier of tuberculosis vaccines for infants was fined and brought to prosecution for cutting the supply of free vaccines in order to sell expensive vaccine products. The Fair Trade Commission fined Korea Vaccine Co. 990 million won (US$830,000) and filed complaints with the prosecution against company staff for [...]

Batavia Biosciences Receives $13.2M Grant to Accelerate Market Access of Low-cost Inactivated Polio Vaccine

Batavia Biosciences Receives $13.2M Grant to Accelerate Market Access of Low-cost Inactivated Polio Vaccine

Leiden, The Netherlands, Feb. 25 (Korea Bizwire) – Batavia Biosciences announced today that it received a $13.2 million grant from the Bill & Melinda Gates Foundation to manufacture clinical-grade inactivated polio vaccine (sIPV), using its newly developed low-cost polio vaccine manufacturing process (marketed as HIP-IPVTM) based on the NevoLine™ manufacturing technology developed by Univercells. In [...]

Inovio HIV Vaccine PENNVAX®-GP Delivered Intradermally Generated Robust, Long-Term Best-In-Class Antibody and T Cell Immune Responses

Inovio HIV Vaccine PENNVAX®-GP Delivered Intradermally Generated Robust, Long-Term Best-In-Class Antibody and T Cell Immune Responses

PLYMOUTH MEETING, Pa., Oct. 25 (Korea Bizwire) — Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its synthetic HIV vaccine PENNVAX®-GP delivered via intradermal route demonstrated durable and robust antibody and T cell immune responses measured throughout the duration of the Phase 1 clinical study. In this reported study, PENNVAX-GP plasmids were delivered intradermally or intramuscularly [...]

Inovio Develops Novel H3N2 Influenza DNA Vaccine That Generates Cross-Reactive Responses and Provides Complete Protection Against Lethal Preclinical Challenges

Inovio Develops Novel H3N2 Influenza DNA Vaccine That Generates Cross-Reactive Responses and Provides Complete Protection Against Lethal Preclinical Challenges

PLYMOUTH MEETING, Pa., Sept. 17 (Korea Bizwire) — Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that its SynCon® vaccine approach using a collection of DNA antigens generated broadly protective antibody responses against the most deadly strains of the H3N2 influenza viruses from the past 50 years and provided complete protection against heterologous lethal challenge in a [...]

Inovio Doses 1st Subject in Phase 1/2 Clinical Trial for Vaccine Against Deadly MERS Infection

Inovio Doses 1st Subject in Phase 1/2 Clinical Trial for Vaccine Against Deadly MERS Infection

PLYMOUTH MEETING, Pa., Sept. 5 (Korea Bizwire) — Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today announced the dosing of the first subject with its vaccine to prevent infection from the deadly MERS virus (Middle East Respiratory Syndrome) in a Phase 1/2a study to evaluate INO-4700 (or GLS-5300). The trial is ongoing in South Korea sponsored [...]

Inovio and Korean Partner Dose 1st Subject in Trial to Develop World’s First Vaccine to Prevent Hepatitis C Infection

Inovio and Korean Partner Dose 1st Subject in Trial to Develop World’s First Vaccine to Prevent Hepatitis C Infection

PLYMOUTH MEETING, Pa., and SEOUL, Korea, Sept. 4 (Korea Bizwire) — Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and GeneOne Life Science (KSE: 011000) today announced they have dosed the first patient in a Phase 1 study designed to evaluate a preventive vaccine against hepatitis C infection. Recruitment has already begun in South Korea, where GeneOne is responsible [...]

Rapid Micro Biosystems Awarded a Contract by Biomedical Advanced Research and Development Authority (BARDA) for the Implementation of a Rapid Sterility Test for Vaccines

Rapid Micro Biosystems Awarded a Contract by Biomedical Advanced Research and Development Authority (BARDA) for the Implementation of a Rapid Sterility Test for Vaccines

LOWELL, Mass., Oct. 23 (Korea Bizwire) — Rapid Micro Biosystems, a leading provider of automated, non-destructive, rapid microbial detection, is pleased to announce the receipt of a $7.3 million contract from the Biomedical Advanced Research and Development Authority (BARDA) for the implementation of a rapid sterility test for vaccines. This awarded grant is part of [...]